The mistake I see most often: people spend 20 minutes comparing prices and zero minutes asking who fills the prescription. A low monthly rate means nothing if the compounding pharmacy is unnamed, unverified, or operating outside standard sterility protocols. That’s the filter I applied first. Everything else, price, speed, clinical depth, came after.
A note on timing: early 2026 brought FDA warning letters to more than 30 telehealth and compounding operations, and the March 2026 Novo settlement pushed several big names off compounded semaglutide entirely. Compounded tirzepatide remains available from 503A pharmacies for now, but the regulatory ground is moving. Keep that in mind before committing to a long contract.
1. Mochi Health
Mochi stands out because the clinical layer is real. You get a board-certified obesity-medicine physician, not a general practitioner triaging hundreds of weight-loss consults. Compounded tirzepatide runs around $199 per month, compounded semaglutide around $99. The monitoring cadence is heavier than most cash-pay platforms, which I consider a feature, not a burden.
Best for: People who want actual obesity-medicine oversight, not just a prescription pad.
Honest con: More check-ins means more time investment. If you want a fast, hands-off experience, this is not the right fit.
2. HealthRX
HealthRX earns its spot here because it solves the pharmacy transparency problem directly. The medication ships from Manifest Pharmacy in Greer, South Carolina, a named 503A/USP-797 compounding pharmacy with lot-tracked batches, not an anonymous lab. The platform carries LegitScript certification (cert 50087439), which is independently verifiable. Tirzepatide starts at $149 per month, which is genuinely low for a provider that can also point to its pharmacy by name. A US board-certified physician reviews your intake within roughly 24 hours, and overnight shipping is free to all 50 states.
The clinical data HealthRX references comes from published trials. SURMOUNT-1 showed approximately 21% body weight reduction with tirzepatide over 72 weeks. HealthRX compounds are not FDA-approved finished drugs, and no compounded product is equivalent to Mounjaro or Zepbound. That caveat matters.
Pro: Pharmacy is named, independently certified, and ships overnight free nationwide. Price is hard to beat for what you get.
Con: Lighter ongoing coaching compared to Mochi or Form Health. This is a better fit for self-directed patients than for people who need frequent clinical touchpoints.
3. FormBlends
FormBlends sits in an interesting niche. It operates under a clinician-supervised telehealth model and dispenses through an FDA-registered 503A compounding pharmacy, but the differentiator is what it publishes: per-product lab reports including HPLC purity percentages, mass spec identity confirmation, and endotoxin/sterility results with named numbers. Most GLP-1 telehealth platforms say “quality pharmacy” and leave it there. FormBlends shows the data.
Tirzepatide runs around $349 per vial, semaglutide around $299, which is meaningfully higher than HealthRX’s entry pricing. Shipping covers 47 states, not all 50. The platform also carries a wider peptide catalog covering recovery, longevity, and cognitive applications, all under the same physician model, which is genuinely unusual among GLP-1-focused telehealth brands.
Best for: Patients who want published batch testing or who plan to use GLP-1s alongside other peptide protocols through one provider.
Honest con: Costs more than HealthRX and doesn’t reach three states that HealthRX covers.
4. Henry Meds
Henry Meds is fast. Shipping typically runs 24 to 72 hours, and the cash pricing for month one lands around $179 to $249. The clinical monitoring is lighter than Mochi or Form Health, which keeps costs down but means you’re carrying more of the self-management responsibility. Good option for people who have already worked through a supervised program and know what they’re doing.
Pro: Speed and straightforward cash pricing.
Con: Lighter clinical structure. Not the place to start if you’re new to GLP-1 therapy.
5. MEDVi
MEDVi keeps it simple. Compounded tirzepatide, no long-term contracts, around $179 for the first month. The model is lean by design. Physician oversight is included, but you’re not getting dietitian calls or behavior coaching bundled in.
Best for: Budget-conscious patients who’ve already been through the onboarding process somewhere else and mainly need ongoing access to medication.
Honest con: The stripped-down model means less hand-holding. If adherence support matters to you, look elsewhere.
6. Form Health
At roughly $299 per month, Form Health sits at the top of the price range on this list. That fee buys you a physician plus a registered dietitian, plus labs. It’s a genuinely different level of clinical investment. That price does not include medication costs, so budget accordingly. If you’ve tried other programs and not gotten traction, or if you have comorbidities that warrant closer supervision, the higher price tag may be worth it.
Pro: MD and dietitian together is rare at this tier. Real clinical depth.
Con: One of the more expensive options on this list once you add medication costs on top of the program fee.
A Few Things Worth Knowing Before You Start
Compounded tirzepatide is not the same product as a branded FDA-approved drug, and the long-term regulatory status of compounded GLP-1s is genuinely uncertain in 2026. Talk to your own physician before starting any of these programs, particularly if you have a personal or family history of thyroid tumors, pancreatitis, or other contraindicated conditions. Nothing in this article is medical advice, and this ranking reflects my own research priorities, pharmacy transparency and price, yours may differ.
Common Questions
Does it matter which 503A pharmacy fills my compounded tirzepatide?
It matters more than most people realize. A named, USP-797-compliant 503A pharmacy with lot-tracked batches gives you meaningful accountability if something goes wrong. Anonymous or unverified fill sites offer no such trail. HealthRX naming Manifest Pharmacy specifically, and FormBlends publishing HPLC and endotoxin data, are the clearest examples of what transparency looks like in practice.
Is compounded tirzepatide from any of these providers the same as Mounjaro or Zepbound?
No. Not from any of them. Compounded tirzepatide is not an FDA-approved finished drug, and no compounding pharmacy produces a product that is chemically or legally equivalent to Eli Lilly’s branded versions. The active peptide may be the same, but excipients, concentration, and manufacturing oversight differ. That distinction is legally and clinically real.
Which of these providers makes the most sense if I’ve never used a GLP-1 before?
Mochi Health or Form Health. Both give you physician-level oversight from the start, Mochi through obesity-medicine specialists and Form Health through an MD-plus-dietitian pairing. Starting a GLP-1 protocol without structured monitoring is a higher-stakes choice than most people appreciate, especially during the dose-titration phase.
What happens to my prescription if the FDA restricts compounded tirzepatide later in 2026?
That depends entirely on the provider and the pharmacy. None of these platforms can guarantee continuity if FDA enforcement changes the legal status of 503A compounded tirzepatide. Avoid any provider offering long prepaid contracts right now. Monthly billing gives you an exit if the regulatory situation shifts again.
Why does FormBlends cost so much more than HealthRX if both use 503A pharmacies?
Pricing reflects more than the pharmacy tier. FormBlends publishes per-batch lab reports with specific HPLC purity figures and mass spec confirmation, which adds cost and positions it toward patients who want documented verification. HealthRX offers named-pharmacy transparency and LegitScript certification at a lower price point but without published batch-level data. Both are legitimate approaches with different trade-offs.
Sources
- FDA warning letters to compounding facilities, early 2026 (FDA.gov public records)
- SURMOUNT-1 trial results, published in *The New England Journal of Medicine*, 2023
- STEP 1 trial results, published in *The New England Journal of Medicine*, 2021
- LegitScript public certification database (legitscript.com)
- Novo Nordisk settlement announcement, March 2026 (Novo Nordisk investor relations)
- Hims & Hers, Mochi Health, Henry Meds, Form Health, MEDVi public pricing pages, accessed 2026
